NetworkNewsBreaks – InMed Pharmaceuticals Inc. (
Post# of 228
(Total Views: 282)
Posted On: 03/16/2022 4:43:31 PM
NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Launching Additional Rare Cannabinoids in Response to Inbound Demand
InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids, has dedicated itself to developing new therapeutic alternatives for the treatment of conditions with high unmet medical needs. The manufacturing process used by InMed and its recently acquired subsidiary BayMedica is unparalleled in the industry. “There is no ‘one-size-fits-all’ approach to cannabinoid manufacturing, so multiple avenues are required to realize the maximum outcome for the targeted cannabinoid. InMed and BayMedica, like a well-oiled machine, work together using biosynthesis, chemical synthesis and the proprietary IntegraSyn(TM) manufacturing models,” a recent article explains. “Together, InMed and BayMedica plan to launch a series of rare cannabinoids into the health and wellness sector during Q1 2022, starting with cannabicitran (‘CBT’). ‘We are delivering on our objective to launch additional rare cannabinoids in early 2022 in response to inbound demand,’ BayMedica SVP and General Manager Shane Johnson said. ‘By midyear, we expect to have at least four rare cannabinoids available for the health and wellness markets, positioning us as a leading large-scale supplier of high-quality rare cannabinoids in these sectors.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids, has dedicated itself to developing new therapeutic alternatives for the treatment of conditions with high unmet medical needs. The manufacturing process used by InMed and its recently acquired subsidiary BayMedica is unparalleled in the industry. “There is no ‘one-size-fits-all’ approach to cannabinoid manufacturing, so multiple avenues are required to realize the maximum outcome for the targeted cannabinoid. InMed and BayMedica, like a well-oiled machine, work together using biosynthesis, chemical synthesis and the proprietary IntegraSyn(TM) manufacturing models,” a recent article explains. “Together, InMed and BayMedica plan to launch a series of rare cannabinoids into the health and wellness sector during Q1 2022, starting with cannabicitran (‘CBT’). ‘We are delivering on our objective to launch additional rare cannabinoids in early 2022 in response to inbound demand,’ BayMedica SVP and General Manager Shane Johnson said. ‘By midyear, we expect to have at least four rare cannabinoids available for the health and wellness markets, positioning us as a leading large-scale supplier of high-quality rare cannabinoids in these sectors.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)